DE69815769D1 - Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms - Google Patents

Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms

Info

Publication number
DE69815769D1
DE69815769D1 DE69815769T DE69815769T DE69815769D1 DE 69815769 D1 DE69815769 D1 DE 69815769D1 DE 69815769 T DE69815769 T DE 69815769T DE 69815769 T DE69815769 T DE 69815769T DE 69815769 D1 DE69815769 D1 DE 69815769D1
Authority
DE
Germany
Prior art keywords
oxidoreductase
antitumor agent
polymer
substrate
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69815769T
Other languages
English (en)
Other versions
DE69815769T2 (de
Inventor
Hiroshi Maeda
Tomohiro Sawa
Takaaki Akaike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69815769D1 publication Critical patent/DE69815769D1/de
Application granted granted Critical
Publication of DE69815769T2 publication Critical patent/DE69815769T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y117/00Oxidoreductases acting on CH or CH2 groups (1.17)
    • C12Y117/03Oxidoreductases acting on CH or CH2 groups (1.17) with oxygen as acceptor (1.17.3)
    • C12Y117/03002Xanthine oxidase (1.17.3.2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
DE69815769T 1997-08-22 1998-08-20 Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms Expired - Lifetime DE69815769T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9240235A JPH1160499A (ja) 1997-08-22 1997-08-22 抗腫瘍剤
JP24023597 1997-08-22

Publications (2)

Publication Number Publication Date
DE69815769D1 true DE69815769D1 (de) 2003-07-31
DE69815769T2 DE69815769T2 (de) 2004-05-19

Family

ID=17056469

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815769T Expired - Lifetime DE69815769T2 (de) 1997-08-22 1998-08-20 Antitumormittel enthaltend einen Komplex einer Oxidoreduktase und eines Polymers und ein Substrat des Enzyms

Country Status (8)

Country Link
EP (1) EP0898968B1 (de)
JP (1) JPH1160499A (de)
KR (1) KR100572603B1 (de)
AT (1) ATE243528T1 (de)
AU (1) AU741472B2 (de)
CA (1) CA2245397C (de)
DE (1) DE69815769T2 (de)
ES (1) ES2202704T3 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157085A1 (en) 1997-08-22 2003-08-21 Hiroshi Maeda Antitumor agents
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
MXPA01010750A (es) 1999-04-23 2003-08-20 Alza Corp Conjugado que tiene un enlace dividible para utilizarse en un liposoma.
AU2001252650A1 (en) * 2000-04-28 2001-11-12 Effector Cell Institute Novel derivative of cell chemotactic factor
US7662781B2 (en) 2005-01-31 2010-02-16 Eci, Inc. Immunopotentiating agent
AU2006238072A1 (en) * 2005-04-18 2006-10-26 Hiroshi Maeda Polymeric pharmaceutical agent for treatment of cancer and process for production of the same
EP1859810A1 (de) * 2006-05-26 2007-11-28 APIT Laboratories GmbH Peg-modifizierte Arginin/lysin-Oxidoreduktase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
EP0505357B1 (de) * 1989-12-11 1999-03-10 Immunomedics, Inc. Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
GB9421223D0 (en) * 1994-10-21 1994-12-07 Univ Alberta Tissue imaging in gene therapy

Also Published As

Publication number Publication date
DE69815769T2 (de) 2004-05-19
CA2245397A1 (en) 1999-02-22
ES2202704T3 (es) 2004-04-01
EP0898968A1 (de) 1999-03-03
KR100572603B1 (ko) 2006-08-01
KR19990023798A (ko) 1999-03-25
AU8079898A (en) 1999-03-04
EP0898968B1 (de) 2003-06-25
JPH1160499A (ja) 1999-03-02
CA2245397C (en) 2005-05-03
ATE243528T1 (de) 2003-07-15
AU741472B2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE60027606D1 (de) Polyphenolisches protein enthaltende bioadhäsive zusammensetzung
IL143748A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
WO1998048852A3 (de) Polymerbeschichtete stents
AU8865998A (en) Improved multiparticulate tablet with quick disintegration
DK1282669T3 (da) Antibegroningssammensætning
ATE243528T1 (de) Antitumormittel enthaltend einen komplex einer oxidoreduktase und eines polymers und ein substrat des enzyms
ATE225665T1 (de) Universell verwendbares bluttplasma
NO20000282D0 (no) Dispersjon av titanpartikler omfattende et bindemiddel basert på polyorganosiloksan
CA2319837A1 (en) Hydroxylation activated drug release
HUP0103572A3 (en) Peg-based macromonomers, chemically inert polymers prepared therefrom and the use of these polymers for organic synthesis and enzyme reactions
AU8334798A (en) A composition comprising an enzyme having galactose oxidase activity and use thereof
AU8796598A (en) Ceramic, glass or metal urinal
CA2234377A1 (en) Aqueous coating composition
MY118864A (en) Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer
ATE493106T1 (de) Oberflächenbehandlungsmittel für dentales hartgewebe
PT1141069E (pt) Composicao de revestimento
DE69842091D1 (de) Frazzled Nukleotidsequenzen, Expressions- produkte, Zusammensetzungen und Verwendungen
EP1048641A4 (de) Apoptose-auslöser
AU1681100A (en) Betacellulin modification
ES1044378U (es) Indicador de paginas multiple y polivalente perfeccionado.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition